This article has multiple issues. Please help improve it or discuss these issues on the talk page. ( Learn how and when to remove these template messages) The topic of this article may not meet Wikipedia's notability guidelines for companies and organizations. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources:  "Digene" –  news · newspapers · books · scholar · JSTOR (February 2020) ( Learn how and when to remove this message) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources:  "Digene" –  news · newspapers · books · scholar · JSTOR (May 2014) ( Learn how and when to remove this message) ( Learn how and when to remove this message)

Digene Corporation was a molecular diagnostics company with company headquarters in Gaithersburg, Maryland, U.S. Floyd Taub, M.D, founded the company in 1984 and it was incorporated in 1985. ^[1] In 1988, the first diagnostic test for human papillomavirus gained FDA approval; the test was ViraPap, developed by Life Technologies, which had been formed by the merger of GIBCO and Bethesda Research Laboratories in 1983. Clinical uptake was slow, and Life sold the test and associated intellectual property to Digene in 1990. It became Digene's most important product line. ^[2]

In 2007, Qiagen bought the company for US$1.6 billion. ^[3]

References